Updated:
Chengdu Yuheng Investment
Zhou Houcheng's Chengdu Yuheng Investment deploys pharmaceutical wealth into healthcare, real estate, and industrial assets across western China.
Chengdu Yuheng Investment
Chengdu Yuheng Investment operates as the investment arm for the wealth generated by Zhou Houcheng's controlling stake in Sichuan New Green Pharmaceutical. The entity is headquartered in Chengdu, with Zhou Houcheng listed as founder. His family member Zhou Qiaomin and long-term business partner Chen Chunchao hold significant executive roles across the group, binding the investment vehicle tightly to the pharmaceutical operating business. The underlying wealth originates from scaled TCM manufacturing, giving the firm a cost-basis advantage in evaluating healthcare-industrial integrations. The firm deploys capital primarily across healthcare services, commercial real estate, and industrial production. Its most visible asset base sits within the New Green Pharmaceutical ecosystem — a network of TCM production bases spanning Nanchang, Tengchong, Bozhou, and a headquarters commercial complex in Pengzhou, Chengdu. The firm also backs a mobile emergency smart Chinese pharmacy fleet, blending healthcare delivery with logistics hardware. Growth-stage operating companies form the core of activity, with capital deployed directly into group subsidiaries rather than structured commingled funds. Scale disclosures are minimal, though the group's physical footprint suggests material deployment in industrial real estate and manufacturing capacity. The firm maintains no separate institutional brand and operates without a known external investor relations function. Zhou Houcheng's political affiliations — with the Zhi Gong Party of China and prior service in the Sichuan Provincial People's Congress — provide the firm a distinct regional operating context. The philanthropic arm is visible through a donation program at Henan University of Chinese Medicine. Yuheng's architecture differs sharply from an institutional investment office: there is no formal fund structure, no disclosed external LP base, and no known separation between pharmaceutical operating cash flows and investment allocation. The investment function shares leadership with the parent company's management, making the entire vehicle essentially a corporate treasury arm operating with the posture of an unregistered investment holding company.
General information
Firm type
Generalist
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Chengdu
Corporate office
Chengdu, Sichuan, China
Principals
Zhou Houcheng
Founder
Zhou Qiaomin
Family Member
Chen Chunchao
Business Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Chengdu Yuheng Investment?
Zhou Houcheng, founder of Sichuan New Green Pharmaceutical, is the core principal driving the investment network. He is supported by family member Zhou Qiaomin and business partner Chen Chunchao, both of whom hold significant roles across the group entities. No external CIO or dedicated investment head has been publicly identified, suggesting Zhou retains final authority over capital allocation.
How is Chengdu Yuheng Investment related to Sichuan New Green Pharmaceutical?
The investment firm functions as the investment vehicle for wealth generated by Zhou Houcheng's pharmaceutical operations. There is no known structural separation between the two — key executives serve across both the pharmaceutical manufacturing side and the investment entity. The investment firm's real asset holdings include multiple TCM production bases tied directly to New Green Pharmaceutical's supply chain (public record).
Does Chengdu Yuheng Investment participate in fund commitments or only direct deals?
Based on the disclosed asset base — which consists entirely of direct operating subsidiaries and physical production bases — the firm appears to allocate exclusively to direct deals and wholly-owned subsidiaries. No track record of LP commitments to external funds has been publicly identified.
What investment sectors does Chengdu Yuheng Investment target?
Healthcare services, real estate, and industrial production form the core allocation. The healthcare focus is specifically anchored in traditional Chinese medicine manufacturing and distribution. Real estate holdings support pharmaceutical operations, and a mobile smart-pharmacy fleet bridges healthcare services with industrial technology.
Does Chengdu Yuheng Investment maintain any philanthropic structures?
Philanthropic activity is visible through a donation program directed at Henan University of Chinese Medicine. The program supports TCM education and is consistent with the firm's healthcare-focused asset base, though no standalone foundation structure has been publicly disclosed.
What is Chengdu Yuheng Investment's known posture on co-investments alongside external GPs?
There is no public record of the firm participating in co-investments alongside external general partners. The group's disclosed holdings consist entirely of proprietary operating subsidiaries and physical assets, suggesting a preference for wholly-owned control rather than minority-position club deals.
Where does the underlying wealth invested by Chengdu Yuheng come from?
The wealth originates from Zhou Houcheng's ownership of Sichuan New Green Pharmaceutical, a scaled manufacturer of traditional Chinese medicine products. The firm's investable capital base is tied to pharmaceutical operating profits rather than a technology exit or diversified holding company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: